Welcome and Introduction: The speakers welcome the delegates to the first Asia Pacific Leukemia Consortium Summit meeting in Bangkok and outline the program and objectives of the summit.

Plenary ALL lecture: Professor Selena Luga from the University of Pennsylvania gives a comprehensive overview of the evolving concepts in measurable residual disease (MRD) and novel therapies in adult B-cell acute lymphoblastic leukemia (B-ALL).

ALL in the Asia-Pacific Region (APLC Survey): Dr. Ashley presented on the APAC ALL survey results which revealed commonalities and variances in the diagnosis, prognostication and treatment of acute lymphoblastic leukemia (ALL) across multiple countries in the Asia Pacific region.

Session 2: Plenary CLL Session

Plenary CLL Lecture: This segment of the APLC Summit Meeting features a plenary lecture by Prof Paolo Lugia on the most practice-changing updates in CLL discussing on BTK and BCL2 inhibitors for CLL. guidelines for CLL management.

APAC CLL Consensus Guidelines: Prof. Eric Tze gave a presentation on the Asian consensus on the diagnosis and management of CLL, based on a literature review and a modified Delphi methodology. He summarized the main consensus statements, which covered topics such as diagnostic criteria, prognostic factors, treatment options, MRD assessment, and supportive care.

Session 3 & 4: Plenary AML and Working Group Session & Industry Engagement

Plenary AML Lecture: Prof Andrew Wei briefly reviewed the 2022 WHO and ELN classifications of AML and highlighted some of the practical challenges and controversies in applying them to clinical practice.

He proceeded to provide an overview of the current treatment landscape of AML, focusing on different age groups, genetic subtypes, and clinical scenarios. He compared the benefits and limitations of various novel agents.

Asia-Pacific Perspective on AML (APLC AML Survey Findings): In this session, results collected from a survey that had 17 respondents was analyzed and the results presented.

The survey highlighted the need for more harmonization and standardization of AML diagnosis and treatment in the Asia-Pacific region. It also identified some unmet needs and gaps in the management of AML patients in the region.

Session 4: Working Group Breakouts (AML)

Industry Presentations: Industry partners took to the stage or played a pre-recording to share on the drug pipeline and took the opportunity to display their areas of interest and their interest to partner APLC in the field of leukemia and related diseases.

Session 5: APLC Working Group Updates and Plans

AML Working Group: Different leads were appointed to look into several areas of focus such as TP53 mutation in AML or AML with MDS, regional treatment recommendation via online platform and clinical trial of frontline gliteritinib.

ALL Working Group: The group discussed the current challenges and variations in the diagnosis, monitoring, and treatment of ALL across different regions. The group identified the priorities relating to treatment protocols, guidelines on PEG asparaginase, registry and HEOR.

CLL Working Group: Action plans for CLL working group were developed to look into recruiting more members, updating APAC CLL consensus guidelines, building registry, clinical trials as well as CLL educational content creation.

Disease Registry, Clinical Trials, Patient Advocacy &amp; Education: In the area of disease registry, steps were discussed to address some of the key issues remain such as data privacy and sharing, data quality and standardization, and data governance and funding.

For clinical trials, a couple of models were suggested as possible frameworks for multi-region clinical trials. It was also recognized that patient advocacy is a space to look into as APLC grows.